

Florida Pharmacy Association

Four Ways to Register
Phone (850) 222-2400
Fax (850) 561-6758
Mail 610 North Adams Street
 Tallahassee, FL 32301
Online at www.pharmview.com

October 17-18, 2015

Meeting Location:
Embassy Suites-Lake Buena Vista S
 4955 Kyngs Heath Rd
 Kissimmee, Florida 34746
For Room Reservation Call:
 (407) 597-4000 or (800) 551-1841
Room Reservation Deadline:
 Friday, September 25, 2015

Hotel Information: FPA suite rates are **\$139 plus tax** for single/double occupancy. An additional charge of \$10 plus tax per person, per night for each additional guest up to 6 maximum guests per suite will apply. The room reservation deadline is **September 25** or until room block is full. Thereafter, reservations will be taken on a space or rate availability basis. Check-in time is 3:00pm /check-out time is 12:00 pm. Self parking is complimentary.

Policy on Industry Support: The FPA adheres to the US Food and Drug Administrator's policy on industry supported educational activities. The FDA policy requires, among other things, that we conduct the educational program supported by any corporate educational grants independently and without control by the grantor of the program's planning, content or execution. Furthermore, the programs must be free of commercial bias for or against any product.

Cancellation Policy: If cancellation is made in writing 30 days prior to the program a refund will be made less a \$10 service charge. If cancellation is made 29-10 days prior to the program, a refund of your registration fee will be made, less a \$50 service charge. Cancellation requested in writing after that date will result in credit for another FPA CE program valid for one year.

ADA Regulations: The FPA complies with ADA requirements. Please contact the office in advance of the meeting for any needed technical assistance.

Tax Deduction: The expense of continuing education, when taken to maintain and improve professional skills is tax deductible. Please contact your accountant.

Children: Under age 18 are not allowed in CE programs.

The speaker handouts will be posted on our website, www.pharmview.com, the week of the conference for you to print and bring to the meeting. Printed booklets are available for purchase at \$25.00.

I would like a printed, hard copy booklet.
 \$_____

Acronyms:

PS-General Pharmacists
 PU-Consultant Pharmacists
 NP-Nuclear Pharmacists
 RPT-Registered Pharmacy Technicians

Registration Form

Pre-Registration Deadline: October 2, 2015

Name _____
 Address _____
 City, State, Zip _____
 Phone _____ (Cell) _____
 Email Address _____
 PS# _____ PU# _____ NP# _____ RPT# _____
 NABP e-profile # _____ DOB (MM/DD) _____

Registration Fees

Two Day Education Registration (12 credit hours)
Excludes: "Medication Errors & New Drug Update"

	Before Oct 2	After Oct 2	Amount
<input type="checkbox"/> Member (PS,PU)	\$190	\$240	\$_____
<input type="checkbox"/> Non Member (PS,PU)	\$295	\$360	\$_____
<input type="checkbox"/> Member (Tech)	\$55	\$70	\$_____
<input type="checkbox"/> Non Member (Tech)	\$75	\$90	\$_____
<input type="checkbox"/> Member (NP)	\$240	\$290	\$_____
<input type="checkbox"/> Non Member (NP)	\$345	\$410	\$_____

Daily Education Registration (6 credit hours)
Excludes: "Medication Errors & New Drug Update"

	Before Oct 2	After Oct 2	Amount
<input type="checkbox"/> Member (PS, PU)	\$145	\$180	\$_____
<input type="checkbox"/> Non Member (PS, PU)	\$195	\$260	\$_____
<input type="checkbox"/> Member (Tech)	\$45	\$60	\$_____
<input type="checkbox"/> Nonmember (Tech)	\$65	\$80	\$_____
<input type="checkbox"/> Member (NP)	\$185	\$230	\$_____
<input type="checkbox"/> Non Member (NP)	\$245	\$310	\$_____

Select the day you will attend: Saturday Sunday

Optional Educational Programs—Separate Fees Apply
(Lunch Provided and Guaranteed for Pre-registrants)

- Saturday, Oct 17 ~ **"Reducing Medication Errors"** (2 credit hours)
 FPA Member - \$40 Non Member - \$60
- Sunday, Oct 18 ~ **"New Drug Update"** (1 credit hour)
 FPA Member - \$40 Non Member - \$60

Onsite Fee: \$50 FPA Member \$70 Non Member Total\$_____

Payment Method: Check (To: FPA) Discover MasterCard Visa **Total Enclosed\$** _____
 Account # _____ Exp Date _____
 Security Code _____ Billing Address _____
 Signature _____



Florida Pharmacy Association
 610 North Adams Street
 Tallahassee, Florida 32301

PRST STD
 U.S. POSTAGE
 PAID
 TALLAHASSEE,
 FL
 PERMIT #801

Visit our website for specially priced Disney Theme Park Tickets for FPA conference attendees. Ticket savings are not available at the front gate of WDW Theme Parks. The deadline for savings via the FPA web link is Friday, October 16, 2015!!!



Who Should Attend?

Consultant Pharmacists
 Nuclear Pharmacists
 Hospital Pharmacists
 Community Pharmacists
 Pharmacy Technicians

Continuing Education Programming

12 Hrs of General/Consultant CE
 12 Hrs of Nuclear CE
 2 Hrs Board Approved Medication Errors
 1 Hr New Drug Update

Dual Track for Consultant and Nuclear Pharmacists
October 17-18, 2015
Embassy Suites - Lake Buena Vista South

Mid-Year Clinical Conference

FLORIDA PHARMACY ASSOCIATION

Nuclear Pharmacy Conference

Saturday Oct 17th: 6 hrs NRC or 8 hrs GCE	Sunday Oct 18th: 6 hrs NRC or 7 hrs GCE
<p>6:30-7:00am Registration Desk Opens</p> <p>7:00-8:00am Education: 1 hr GCE/NRC/TECH Radiopharmaceutical Bone Palliation Therapy <i>George H. Hinkle, RPh, MS, BCNP, FAPhA, FASHP, Professor of Pharmacy Practice, Ohio State University.</i> Upon completion of this activity, participants will be able to: Describe the "ideal" therapeutic radiopharmaceutical; Provide a summary of the treatment modalities for painful osseous metastases; Explain how radiation interaction with matter can be used to treat disease; Compare the four radiopharmaceuticals used for bone pain palliation. UAN: 0165-0000-15-090-L04-P UAN: 0165-0000-15-090-L04-T</p> <p>8:00-9:00am Education: 1 hr GCE/NRC/TECH The Radiopharmaceutical Management of Localized Prostate Cancer and Evaluation of Treatment Response <i>Brian J. Davis, MD, PhD, Professor of Radiation Oncology, Mayo Medical School.</i> Upon completion of this activity, participants will be able to: Review the diagnosis and management of men with prostate cancer; Explain techniques and outcomes of radiation therapy for prostate cancer; Discuss the role of advanced imaging including PET imaging in the radiotherapeutic management of localized and oligometastatic prostate cancer. UAN: 0165-0000-15-091-L04-P UAN: 0165-0000-15-091-L04-T</p> <p>9:00-10:00am Education: 1 hr GCE/NRC/TECH Molecular Imaging of Prostate Cancer to Improve Image-directed Therapy <i>Geoffrey Johnson, MD, PhD, Assistant Professor of Radiology and Immunology, Director, Nuclear Radiology Fellowship, Mayo Clinic.</i> Upon completion of this activity, participants will be able to: Discuss the physiology of prostate cancer relative to targets for imaging; Explain PET imaging for staging and recurrence evaluation, including C-11 choline and other nuclear medicine imaging drugs; Identify regulatory issues for PET used in prostate cancer. UAN: 0165-0000-15-092-L04-P UAN: 0165-0000-15-092-L04-T</p> <p>10:00-10:15am BREAK</p> <p>10:15-11:15am Education: 1 hr GCE/NRC/TECH Overview of Breast Cancer and Breast Imaging Modalities <i>Mark Redick, MD, Assistant Professor of Radiology, University of Kansas Medical Center.</i> Upon completion of this activity, participants will be able to: Provide an overview of breast cancer including the types and stages of breast cancer; Provide a review of breast imaging modalities (e.g. mammography, ultrasound, MRI, PET/CT); Discuss the role of breast imaging in breast cancer screening, diagnosis, staging, and management. UAN: 0165-0000-15-093-L04-P UAN: 0165-0000-15-093-L04-T</p> <p>11:15-12:15pm Education: 1 hr GCE/NRC/TECH Multidisciplinary Treatment Approach to Breast Cancer <i>Jamie L. Wagner, DO, FACOS, Assistant Professor of Surgery, University of Kansas Medical Center.</i> Upon completion of this activity, participants will be able to: Discuss the treatment options for different stages of breast cancer; Differentiate between local and systemic breast cancer treatments; Describe the surgical therapy options for breast cancer treatment. UAN: 0165-0000-15-094-L04-P UAN: 0165-0000-15-094-L04-T</p> <p>12:15-1:15pm Education: 1 hr GCE/NRC/TECH Up and Coming Research Radiopharmaceutical Agents <i>Dao Le, PharmD, BCNP, Director, Nuclear Medicine Radiopharmacy, M.D. Anderson Cancer Center.</i> Upon completion of this activity, participants will be able to: Provide an overview in the area of diagnostic and theranostic research radiopharmaceutical agents; Describe the potential clinical utility of promising research radiopharmaceutical agents (e.g. Ac-225, Ra-225, Lu-177, Cu-64, I-124, Zr-89); Discuss the role of the nuclear pharmacist/technician in an academic research institution. UAN: 0165-0000-15-095-L04-P UAN: 0165-0000-15-095-L04-T</p> <p>1:30-3:30pm Education: 2hrs GCE/TECH Reducing Medication Errors (Separate Registration Fee Required) <i>Michael Jackson, BPharm, CPh, Executive Vice President and CEO, FPA.</i> Upon completion of this activity, pharmacist will be able to: Define elements of a Continuous Quality Improvement (CQI) Program; Restructure a pharmacy practice to address quality related events; Analyze some common causes of quality related events; Implement an action plan to address quality of care in pharmacies with a goal towards error reduction and prevention; Recite quality improvement regulations for Florida pharmacies. Upon completion technicians will be able to: Define CQI; List most common medication errors; Employ techniques to reduce medication errors by using CQI. UAN: 0165-0000-15-102-L05-P UAN: 0165-0000-15-102-L05-T</p>	<p>6:30-7:00am Registration Desk Opens</p> <p>7:00-8:00am Education: 1 hr GCE/NRC/TECH Compounding vs. Manufacturing – Review Current Standards <i>Kara Duncan Weatherman, PharmD, BCNP, FAPhA, Assistant Professor of Nuclear Pharmacy, Purdue University – College of Pharmacy.</i> Upon completion of this activity, participants will be able to: Compare compounding and manufacturing and examine the differences between the two; Analyze the current regulatory environment with respect to compounding; Interpret the current practice and regulatory standards as they relate to practice based issues. UAN: 0165-0000-15-096-L04-P UAN: 0165-0000-15-096-L04-T</p> <p>8:00-9:00am Education: 1 hr GCE/NRC/TECH Past, Present and Future of Lymphatic Mapping <i>George H. Hinkle, RPh, MS, BCNP, FAPhA, FASHP, Professor of Pharmacy Practice, Ohio State University.</i> Upon completion of this activity, participants will be able to: Describe the lymph system - anatomy, physiology, disease spread, clinical significance; Describe the lymph system detection methods; Compare and contrast current radiopharmaceuticals for lymphatic mapping and imaging; List three disease states where lymphatic mapping and imaging are valuable for patient care. UAN: 0165-0000-15-097-L04-P UAN: 0165-0000-15-097-L04-T</p> <p>9:00-10:00am Education: 1 hr GCE/NRC/TECH Nuclear Pharmacy's Ever Changing Regulatory Environment and the New Challenges this Practice Setting <i>Duann Thistlethwaite, RPh, BCNP, FAPhA, Surveyor / Consultant, National Association of Boards of Pharmacy.</i> Upon completion of this activity, participants will be able to: Describe the different regulatory bodies and their role in nuclear pharmacy practice; Discuss the differences between inspections and accreditation processes; Describe ways to incorporate regulatory requirements and accreditation expectations into everyday nuclear pharmacy practice. UAN: 0165-0000-15-098-L04-P UAN: 0165-0000-15-098-L04-T</p> <p>10:00-10:15am BREAK</p> <p>10:15-11:15am Education: 1 hr GCE/NRC/TECH Advances in Neuroimaging & Diagnostic Accuracy in the Continuum of Cognitive Decline <i>Geoffrey Johnson, MD, PhD, Assistant Professor of Radiology and Immunology, Director, Nuclear Radiology Fellowship, Mayo Clinic.</i> Upon completion of this activity, participants will be able to: Discuss the imaging options for patients in cognitive change evaluations; Discuss the reliability/utility of imaging in clinical dementia and clinical dilemmas; Discuss the utility of imaging in understanding the normal aging process in the brain; Discuss current reimbursement issues with neuroimaging in patients. UAN: 0165-0000-15-099-L04-P UAN: 0165-0000-15-099-L04-T</p> <p>11:15-12:15pm Education: 1 hr GCE/NRC/TECH Neuro-PET Imaging: Value in Parkinson's Disease, Epilepsy, and the Effects of Medical Marijuana <i>Edward Bednarczyk, PharmD, FCCP, Clinical Associate Professor, University of Buffalo – New York School of Pharmacy.</i> Upon completion of this activity, participants will be able to: Describe the pathophysiology of Parkinson's Disease and Seizure Disorders; Describe the role of anatomic and molecular imaging techniques used in Parkinson's Disease and Seizure Disorders; List the challenges of assessing the pharmacotherapeutic application of cannabinoids versus medical marijuana. UAN: 0165-0000-15-100-L04-P UAN: 0165-0000-15-100-L04-T</p> <p>12:15-1:15pm Education: 1 hr GCE/NRC/TECH Review of FDA-Approved PET Agents & Promising PET Research Agents <i>Dao Le, PharmD, BCNP, Director, Nuclear Medicine Radiopharmacy, M.D. Anderson Cancer Center.</i> Upon completion of this activity, participants will be able to: Provide an overview of the drug development process; Discuss the FDA approved PET radiopharmaceutical agents; Identify promising PET radiopharmaceutical agents; Explore the future directions of PET. UAN: 0165-0000-15-101-L04-P UAN: 0165-0000-15-101-L04-T</p> <p>1:30-2:30pm Education: 1 hr GCE/TECH New Drug Update (Separate Registration Fee Required) <i>Shawn Bridley, PharmD, CGP, CPh, Geriatric Pharmacist, Owner of Care Dynamics Senior Care.</i> Upon completion of this activity, pharmacists will be able to: Compare and contrast newly approved drugs with older agents regarding their safety, efficacy, dosing and cost; List pipeline drugs expected to be released in the coming year. Upon completion technicians will be able to: Recognize new drugs to be released; Identify indications of newly released drugs. UAN: 0165-0000-15-103-L04-P UAN: 0165-0000-15-103-L04-T</p>

Men and Women Health Clinical Conference

Saturday Oct 17th: 6 hrs RC or 8 hrs GCE	Sunday Oct 18th: 6 hrs RC or 7 hrs GCE
<p>6:30-7:00am Registration Desk Opens</p> <p>7:00-8:30am Education: 1.5 hrs GCE/TECH/RC Managing Sexual Dysfunction in Men <i>Dana Brown, PharmD, BCPS, Assistant Dean for Academics, Associate Professor of Pharmacy Practice, Lloyd L. Gregory School of Pharmacy.</i> Upon completion of this activity, pharmacists will be able to: Explain the etiology, including pathophysiology and contributing factors, of male sexual dysfunction; Given a male patient, classify the type of sexual dysfunction he is experiencing; Discuss the adverse effects, role in therapy and significant drug-drug interactions associated with sexual dysfunction treatment options; Describe appropriate strategies to utilize in patient with erectile dysfunction who is not responding to traditional therapy recommendations; Explain patient characteristics that would make various sexual dysfunction treatment modalities inappropriate in men (i.e. contraindications); Provide appropriate nonpharmacologic and pharmacologic recommendations for a patient with sexual dysfunction based on patient-specific parameters; Counsel a patient on the appropriate administration and potential adverse effects of various sexual dysfunction treatment modalities. Upon completion technicians will be able to: Define ED; Recognize causes of ED; List the different types of sexual dysfunction; Recognize medications used to treat ED UAN: 0165-0000-15-104-L01-P UAN: 0165-0000-15-104-L01-T</p> <p>8:30-10:00am Education: 1.5 hrs GCE/TECH/RC Light at End of the Tunnel: The Pharmacist's Role in Managing Depression <i>Shawn Bridley, PharmD, CGP, CPh, Board Certified Geriatric Pharmacist, Owner of Care Dynamics Senior Care.</i> Upon completion of this activity, pharmacist will be able to: Define depression and describe its pathophysiology, available assessment tools, and impact on patient health; Summarize current guidelines for depression diagnosis and treatment; Discuss available pharmacologic and nonpharmacologic drug therapies for depression treatment; Describe the role of the pharmacist in depression management. Upon completion technicians will be able to: Define depression; List signs and symptoms of depression; Recognize medications used to treat depression. UAN: 0165-0000-15-105-L01-P UAN: 0165-0000-15-105-L01-T</p> <p>10:00-10:15am BREAK</p> <p>10:15-11:45am Education: 1.5 hrs GCE/TECH/RC Management of Menopausal Symptoms <i>Patty Ghazvini, PharmD, CGP, Professor of Pharmacy Practice, FAMU College of Pharmacy.</i> Upon completion of this activity, pharmacists will be able to: Define menopause and describe its physiology and impact on patient health; Summarize treatment guidelines for management of menopausal symptoms including doses and formulations; Discuss the use of bioidentical hormone therapy for management of menopausal symptoms; Recognize adverse effects and drug interactions associated with the different agents; Provide counseling tips regarding the use of different products. Upon completion technicians will be able to: Define menopause; List signs and symptoms of menopause; Identify products used to treat menopause. UAN: 0165-0000-15-106-L01-P UAN: 0165-0000-15-106-L01-T</p> <p>11:45-1:15pm Education: 1.5 hrs GCE/TECH/RC Prevention and Management of Osteoporosis <i>Patty Ghazvini, PharmD, CGP, Professor of Pharmacy Practice, FAMU College of Pharmacy.</i> Upon completion of this activity, pharmacist will be able to: Explain how hormones affect bone metabolism and who is most at risk for developing osteoporosis; Identify the role of calcium, vitamin D, phosphorous and phytoestrogens in bone metabolism; List key risk factors for osteoporosis; Identify useful assessment tools in patients with osteoporosis; Discuss current pharmacological therapies available for the prevention and treatment of osteopenia and osteoporosis including side effects and drug interactions; Provide patient counseling tips regarding the different products. Upon completion technicians will be able to: Define osteoporosis; List risk factors for osteoporosis; Identify products used to treat osteoporosis. UAN: 0165-0000-15-107-L01-P UAN: 0165-0000-15-107-L01-T</p> <p>1:30-3:30pm Education: 2hrs GCE/TECH Reducing Medication Errors (Separate Registration Fee Required)</p>	<p>6:30-7:00am Registration Desk Opens</p> <p>7:00-8:30am Education: 1.5 hrs GCE/TECH/RC Urine Luck! A Review of the Management of Benign Prostatic Hyperplasia <i>Dana Brown, PharmD, BCPS, Assistant Dean, Associate Professor, PBAU.</i> Upon completion of this activity, pharmacists will be able to: Explain the pathophysiology of benign prostatic hyperplasia (BPH), including factors which can worsen BPH; Recognize the clinical presentation of BPH, including common signs and symptoms; Provide appropriate non-pharmacologic and pharmacologic recommendations for a BPH patient; Counsel a patient on the appropriate administration and potential adverse effects of various BPH treatment modalities; Compare and contrast BPH treatment modalities with regards to adverse effects, role in therapy, and drug-drug interaction considerations; Explain patient characteristics that would make various BPH treatment modalities inappropriate (i.e. contraindications). Upon completion technicians will be able to: Define BPH; Identify signs and symptoms of BPH; Recognize medications used to treat BPH. UAN: 0165-0000-15-108-L01-P UAN: 0165-0000-15-108-L01-T</p> <p>8:30-10:00am Education: 1.5 hrs GCE/TECH/RC The Ups and Downs of Weight and Management and Obesity <i>Carol Motycka, PharmD, BCACP, Clinical Associate Professor, Assistant Dean and Campus Director, University of Florida Jacksonville.</i> Upon completion of this activity, pharmacists will be able to: Evaluate the risk factors that contribute to overweight and obesity; Interpret possible causes for overweight and obesity and how to prevent them; Identify potential complications associated with obesity in adults and children; Analyze a patient to determine if they are a candidate for pharmacotherapy treatment of obesity; Recommend treatment options for obesity in both children and adults and discuss the risks and benefits of each treatment; Summarize potential pharmacokinetic issues with medications following gastric surgery. Upon completion technicians will be able to: Identify risk factors that lead to obesity; List ways to prevent obesity; Recognize treatment options for obesity. UAN: 0165-0000-15-109-L01-P UAN: 0165-0000-15-109-L01-T</p> <p>10:00-10:15am BREAK</p> <p>10:15-11:45am Education: 1.5 hrs GCE/TECH/RC Cancer of the Breast, Prostate, and Lungs: What Every Pharmacist Should Know About the Three Leading Types of Cancer <i>Kenneth S Bauer Jr, PharmD, PhD, Professor of Pharmacy Practice and Pharmaceutical Sciences, LECOM School of Pharmacy.</i> Upon completion of this activity, pharmacists will be able to: <u>Cancer</u>: Identify the trends in cancer prevalence and mortality; Identify the primary risk factors for developing any type of cancer; <u>Breast cancer</u>: Identify risk factors for signs and symptoms of breast cancer; Identify the treatment goals for early stage breast cancer and metastatic breast cancer; Review treatment strategies for early stage breast cancer and metastatic breast cancer; <u>Prostate Cancer</u>: List at least 3 risk factors associated with prostate cancer; Explain the current recommendations for prostate cancer screening; Describe how the stage of disease affects the treatment scheme; Describe the regulation of prostate cancer growth; Describe the current treatment strategies used for patients with advanced prostate cancer; <u>Lung Cancer</u>: Discuss the epidemiology, etiology, pathophysiology of lung cancer; Describe the risk factors and risk reduction/screening for lung cancer; Describe the most appropriate patient-specific therapy and monitoring for both small-cell and non-small cell lung cancer. Upon completion technicians will be able to: List cancer risk factors; Identify signs/symptoms of cancer; Recognize treatment strategies. UAN: 0165-0000-15-110-L01-P UAN: 0165-0000-15-110-L01-T</p> <p>11:45-1:15pm Education: 1.5 hrs GCE/TECH/RC Use of Drugs During Pregnancy and Lactation <i>Fallon Enfinger, PharmD, CDE, Assistant Professor of Pharmacy Practice, LECOM School of Pharmacy.</i> Upon completion of this activity, pharmacists will be able to: Explain pharmacokinetic changes during pregnancy; Explain the general principles of drug transfer across the placenta and into breast milk; Discuss considerations of drug selection in pregnancy; Review the most recent updates to the FDA categories for the use of medications during pregnancy; Explain the need for folic acid supplementation in pregnancy; Identify common acute and chronic conditions associated with pregnancy and the appropriate treatment options available; Identify specified teratogens, drugs with non-teratogenic adverse effects, and safe drugs for use during pregnancy and breastfeeding; Counsel pregnant and breastfeeding patients on appropriate medication use; Aid patients and providers in selecting the appropriate pharmacotherapy for pregnant and breastfeeding patients while weighing risk versus benefit. Upon completion technicians will be able to: Identify how drugs transfer from the mother to the fetus; Recognize current FPA categories for medications in pregnancy; Recognize the importance of folic acid in pregnancy. UAN: 0165-0000-15-111-L01-P UAN: 0165-0000-15-111-L01-T</p> <p>1:30-2:30pm Education: 1 hr GCE/TECH New Drug Update 2015 (Separate Registration Fee Required)</p>



The Florida Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Up to 15 contact hours are available upon successful completion of attendance and evaluation forms. Universal Activity Numbers (UAN) above. Statements of continuing education will be available for you to download and print within six weeks. This is an ACPE knowledge based activity (nuclear) and application based activity (clinical). Consultant number pending. Speakers have no relevant financial relationship to the activities.